Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Alfentanil | hsa00052 | Galactose metabolism | 1.06E-03 | 2 | P06280, O43451 | GLA, MGAM | More | | Alfentanil | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Alfentanil | hsa00220 | Arginine biosynthesis | 1.43E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | | Alfentanil | hsa00500 | Starch and sucrose metabolism | 8.89E-07 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Alfentanil | hsa00730 | Thiamine metabolism | 2.92E-05 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Alfentanil | hsa00770 | Pantothenate and CoA biosynthesis | 7.90E-03 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Alfentanil | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.58E-04 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Alfentanil | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | Alfentanil | hsa03008 | Ribosome biogenesis in eukaryotes | 4.42E-02 | 3 | Q9NYH9, P78345, Q9BVP2 | UTP6, RPP38, GNL3 | More | | Alfentanil | hsa03013 | RNA transport | 2.29E-04 | 13 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, TACC3, FXR1 | More | | Alfentanil | hsa04062 | Chemokine signaling pathway | 3.93E-03 | 10 | P25024, P25025, P47992, Q9UBD3, P07948, P63218, P50151, P49407, Q08881, P49841 | CXCR1, CXCR2, XCL1, XCL2, LYN, GNG5, GNG10, ARRB1, ITK, GSK3B | More | | Alfentanil | hsa04064 | NF-kappa B signaling pathway | 4.92E-02 | 6 | P10415, P51617, Q13546, Q9UDY8, Q13077, P24522 | BCL2, IRAK1, RIPK1, MALT1, TRAF1, GADD45A | More | | Alfentanil | hsa04070 | Phosphatidylinositol signaling system | 4.07E-02 | 4 | P0DP23, Q14643, O14732, P17252 | CALM1, ITPR1, IMPA2, PRKCA | More | | Alfentanil | hsa04071 | Sphingolipid signaling pathway | 1.82E-04 | 9 | P17252, Q9H228, P01375, Q13362, Q16537, Q9BX95, P04637, P10415, Q9UQC2 | PRKCA, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, TP53, BCL2, GAB2 | More | | Alfentanil | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | | Alfentanil | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.44E-02 | 5 | Q16537, P0DP23, P17252, P10415, P20020 | PPP2R5E, CALM1, PRKCA, BCL2, ATP2B1 | More | | Alfentanil | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Alfentanil | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Alfentanil | hsa04380 | Osteoclast differentiation | 1.02E-02 | 6 | Q9UQC2, Q16539, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, IL1R1, FCGR3B, TNF, LILRA2 | More | | Alfentanil | hsa04612 | Antigen processing and presentation | 4.68E-04 | 8 | P13765, P48382, P26715, P26717, Q07444, Q13241, O43908, P01732 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRC3, KLRD1, KLRC4, CD8A | More | | Alfentanil | hsa04613 | Neutrophil extracellular trap formation | 1.68E-02 | 9 | P17252, O60603, P08246, Q92769, Q6FI13, P33778, P14598, Q15080, P21462 | PRKCA, TLR2, ELA2, HDAC2, H2AC18; H2AC19, H2BC3, NCF1, NCF4, FPR1 | More | | Alfentanil | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | Alfentanil | hsa04625 | C-type lectin receptor signaling pathway | 3.87E-02 | 4 | Q9ULY5, P20749, P01375, Q16539 | CLEC4E, BCL3, TNF, MAPK14 | More | | Alfentanil | hsa04650 | Natural killer cell mediated cytotoxicity | 6.61E-08 | 12 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O14931, O75015, P26717, Q07444, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC3, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.771 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.797 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.78 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.767 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.818 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.726 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | Q07444 | KLRC3 | NKG2-E type II integral membrane protein | 0.829 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.726 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 |
| Alfentanil | hsa04657 | IL-17 signaling pathway | 1.27E-03 | 5 | O00463, Q16539, P49841, P14780, P01375 | TRAF5, MAPK14, GSK3B, MMP9, TNF | More | | Alfentanil | hsa04658 | Th1 and Th2 cell differentiation | 7.09E-05 | 7 | Q04759, P20963, P09693, P06239, P23771, Q9UL17, Q13761 | PRKCQ, CD247, CD3G, LCK, GATA3, TBX21, RUNX3 | More | | Alfentanil | hsa04659 | Th17 cell differentiation | 2.34E-03 | 6 | Q04759, P06239, Q9UL17, P23771, P09693, P20963 | PRKCQ, LCK, TBX21, GATA3, CD3G, CD247 | More | | Alfentanil | hsa04660 | T cell receptor signaling pathway | 1.12E-05 | 11 | P01375, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Alfentanil | hsa04664 | Fc epsilon RI signaling pathway | 3.98E-02 | 3 | P01375, Q16539, Q9UQC2 | TNF, MAPK14, GAB2 | More | | Alfentanil | hsa04666 | Fc gamma R-mediated phagocytosis | 2.22E-02 | 4 | P49006, P06396, P14598, P17252 | MARCKSL1, GSN, NCF1, PRKCA | More | | Alfentanil | hsa04668 | TNF signaling pathway | 2.21E-02 | 5 | P01375, O00463, Q16539, P20749, P14780 | TNF, TRAF5, MAPK14, BCL3, MMP9 | More | | Alfentanil | hsa04720 | Long-term potentiation | 4.42E-02 | 3 | P17252, P0DP23, Q14643 | PRKCA, CALM1, ITPR1 | More | | Alfentanil | hsa04728 | Dopaminergic synapse | 2.82E-02 | 6 | P14416, P63218, P50151, P49841, Q16539, P49407 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1 | More | | Alfentanil | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Alfentanil | hsa04912 | GnRH signaling pathway | 4.42E-02 | 3 | P17252, Q14643, P0DP23 | PRKCA, ITPR1, CALM1 | More | | Alfentanil | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Alfentanil | hsa04925 | Aldosterone synthesis and secretion | 1.54E-02 | 4 | Q14643, P0DP23, P17252, P20020 | ITPR1, CALM1, PRKCA, ATP2B1 | More | | Alfentanil | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Alfentanil | hsa04966 | Collecting duct acid secretion | 3.15E-02 | 2 | P02730, Q9Y666 | SLC4A1, SLC12A7 | More | | Alfentanil | hsa04970 | Salivary secretion | 1.00E-02 | 4 | Q14643, P20020, P17252, P0DP23 | ITPR1, ATP2B1, PRKCA, CALM1 | More | | Alfentanil | hsa04972 | Pancreatic secretion | 1.00E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | Alfentanil | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | | Alfentanil | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.11E-02 | 4 | Q16539, P25024, P25025, P07948 | MAPK14, CXCR1, CXCR2, LYN | More | | Alfentanil | hsa05132 | Salmonella infection | 1.02E-03 | 10 | P51617, Q9UJU2, Q13546, P10415, O75369, O60603, Q9BQS8, P51808, Q13561, Q13509 | IRAK1, LEF1, RIPK1, BCL2, FLNB, TLR2, FYCO1, DYNLT3, DCTN2, TUBB3 | More | | Alfentanil | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | Alfentanil | hsa05140 | Leishmaniasis | 1.56E-02 | 5 | P14598, O60603, P49006, P51617, Q15080 | NCF1, TLR2, MARCKSL1, IRAK1, NCF4 | More | | Alfentanil | hsa05144 | Malaria | 1.64E-03 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | Alfentanil | hsa05146 | Amoebiasis | 2.73E-02 | 4 | P09341, P05089, P12814, P08311 | CXCL1, ARG1, ACTN1, CTSG | More | | Alfentanil | hsa05163 | Human cytomegalovirus infection | 1.46E-03 | 8 | P01375, P63218, P50151, P49841, P14778, P25025, Q16539, O00463 | TNF, GNG5, GNG10, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | | Alfentanil | hsa05169 | Epstein-Barr virus infection | 2.54E-02 | 8 | Q92769, P04637, Q13546, P10415, P24522, O60603, P51617, P09693 | HDAC2, TP53, RIPK1, BCL2, GADD45A, TLR2, IRAK1, CD3G | More | | Alfentanil | hsa05170 | Human immunodeficiency virus 1 infection | 6.54E-03 | 9 | P0DP23, P17252, Q13546, Q14643, P51617, O60603, P09693, P10415, Q9Y6Q5 | CALM1, PRKCA, RIPK1, ITPR1, IRAK1, TLR2, CD3G, BCL2, AP1M2 | More | | Alfentanil | hsa05212 | Pancreatic cancer | 3.40E-02 | 1 | P37173 | TGFBR2 | More | | Alfentanil | hsa05214 | Glioma | 1.00E-02 | 4 | P0DP23, P17252, P04637, P24522 | CALM1, PRKCA, TP53, GADD45A | More | | Alfentanil | hsa05216 | Thyroid cancer | 1.85E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Alfentanil | hsa05217 | Basal cell carcinoma | 4.42E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Alfentanil | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.88E-03 | 5 | O95267, P20963, P09693, P06239, Q04759 | RASGRP1, CD247, CD3G, LCK, PRKCQ | More | | Alfentanil | hsa05322 | Systemic lupus erythematosus | 1.57E-02 | 4 | P08311, P62807, Q16778, P12814 | CTSG, HIST1H2BC, HIST2H2BE, ACTN1 | More | | Alfentanil | hsa05418 | Fluid shear stress and atherosclerosis | 1.94E-04 | 7 | Q16539, Q14145, P10599, P14780, P01375, P14778, P27930 | MAPK14, KEAP1, TXN, MMP9, TNF, IL1R1, IL1R2 | More | | |